LixiLan-O Study

Lixilan-O study

LixiLan-O Study

Download this clinical summary to read about the benefits of Suliqua in the phase III LixiLan-O study. The study is demonstrating the benefits of Suliqua, a titratable fixed-ratio combination of insulin glargine + lixisenatide vs insulin glargine + lixisenatide monocomponents. This was done in type 2 diabetes patients, inadequately controlled on oral agents. 
Rosenstock J, et al. Diabetes Care. 2016; 39: 2026–35.

Lady talking on phone

Always up to date?

Webinars, evidence, expert video’s, peer-to-peer events… Do you want to be the first to know when new, relevant information is available? Let us know and we’ll send you a message.

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy.
By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.
Accept and close